



King's Research Portal

DOI:

[10.1111/pai.13443](https://doi.org/10.1111/pai.13443)

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Peters, R. L., Krawiec, M., Koplin, J. J., & Santos, A. F. (2020). Update on Food Allergy. *Pediatric Allergy and Immunology*. <https://doi.org/10.1111/pai.13443>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

Update on Food Allergy

Rachel L Peters^{1,2}, Marta Krawiec^{3,4,5}, Jennifer J Koplin^{1,2,6}, Alexandra F. Santos^{3,4,5,7}

¹Murdoch Children's Research Institute Melbourne, VIC, Australia

²Department of paediatrics, University of Melbourne, Melbourne, VIC, Australia.

³Children's Allergy Service, Guy's and St. Thomas' NHS Foundation Trust, London, UK

⁴Department of Women and Children's Health (Paediatric Allergy), School of Life Course Sciences, Faculty of Life Sciences and Medicine, King's College London, London, UK

⁵Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK

⁶School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.

⁷Asthma UK Centre for Allergic Mechanisms of Asthma, London, UK

Corresponding author:

Name: Dr Alexandra Santos

Postal address: Department of Pediatric Allergy, 2nd floor, South Wing, St Thomas' Hospital, 28 Westminster Bridge Road, SE1 7EH London, United Kingdom

Telephone: +44(0)2071886424

Fax: +44(0) 2074038640

Email address: Alexandra.santos@kcl.ac.uk

Word Count: 3860

Number of Tables: 2

Number of Figures: 1

Keywords: food allergy, diagnosis, immunotherapy, biologics, IgE, skin prick test, basophil activation test

Conflicts of interest: Alexandra F. Santos reports grants and personal fees from Medical Research Council (MR/M008517/1); grants from Asthma UK and the NIHR through the Biomedical Research Centre (BRC) award to Guy's and St Thomas' NHS Foundation Trust,

during the conduct of the study; grants from Immune Tolerance Network/National Institute of Allergy and Infectious Diseases (NIAID, NIH), grants from Asthma UK; personal fees from Thermo Scientific, Nutricia, Infomed, Novartis, Allergy Therapeutics, Buhlmann, as well as research support from Buhlmann and Thermo Scientific through a collaboration agreement with King's College London. RLP and JK receive research support from the National Health and Medical Research Council of Australia. The other authors declare no conflicts of interest.

Abstract:

Food allergy is a major public health issue with growing prevalence in the urbanized world and significant impact on the lives of allergic patients and their families. Research into the risk factors that have contributed to this increase and their underlying immune mechanisms could lead us to definitive ways for treatment and prevention of food allergy. For the time being, introduction of peanut and other allergenic foods in the diet at the time of weaning seems to be an effective way to prevent the development of food allergy. Improved diagnosis and appropriate management and support of food allergic patients are central to patient care with food immunotherapy and biologicals making the transition to clinical practice. With the new available treatments it is becoming increasingly important to include patient's and family preferences to provide a management plan tailored to their needs.

Abstract word count: 140

Impact of food allergy

Food allergy (FA) affects about 8% of children in the Western countries and seems to be rising in other parts of the world, particularly in urban rather than rural areas of countries such as Vietnam and South Africa, and other parts of Asia and Africa¹⁻⁴. The prevalence of FA has increased over the recent decades, as have the number of hospitalizations for food-induced anaphylaxis, following what seems to be the “second wave of the allergy epidemic” after the rise in prevalence of asthma and respiratory allergy in previous decades⁵⁻⁷. Pouessel et al⁸ have shown that foods caused 37% of cases of ICU admissions for anaphylaxis and 79% of recurrent anaphylaxis. Self-reported FA is even more common with an often underappreciated impact¹. Gupta et al¹ report that about 40% of children report multiple food allergies, often severe food allergies, and carry an adrenaline auto-injector. In Western countries, such as the US and the UK, FA affects disproportionately children from ethnic minorities, such as children of Afro-Caribbean descent^{1,9,10}. Whether this has to do with genetic predisposition in face of environmental factors related to the modern life-style or whether the cultural background, the history of inequality and different access to healthcare also play a role, it is unclear^{10,11}. The three-fold higher risk of peanut and other food allergies in infants born in Australia to Asian born parents compared with the risk of peanut allergy in infants born to Australian-born parents reinforced this discrepancy reinforce the rapidity with which these changes occur and the importance of gene-environment interactions, that need to be further explored¹².

There is no curative treatment for FA and the mainstay of management is allergen avoidance. Emergency medication needs to be made available to patients to enable them to treat acute allergic reactions that may result from accidental exposure to the culprit allergens, which are unfortunately common¹³. Allergen avoidance imposes dietary restrictions, with potential nutritional consequences and can lead to food insecurity¹⁴⁻¹⁶. Eighty six per cent of mothers of children with suspected FA avoid foods on their own initiative¹⁷. Goldberg et al¹⁶ have recently shown that milk allergic young adults have reduced bone mineral density and that low calcium intake, asthma and weight constitute independent risk factors. FA can also result in an impairment of quality of life and mental health of children and their families¹⁷⁻²⁰. For instance, mothers of children with suspected FA have higher state and trait anxiety scores than healthy controls¹⁷ and about 50% of children and teenagers with FA experience

bullying¹⁸. FA can also impact negatively on the costs, not only related to the healthcare but also the indirect costs, for instance related to school and work absences, and the financial burden on the families themselves, resulting for example from the need to spend more time shopping and to find alternative foods, that are often more expensive. All these factors account for additional negative impact on the lives of children with FA and their families, that goes beyond the state of hypersensitivity to the culprit allergens, and underscore the importance of an accurate diagnosis and the search for specific treatments for FA.

Epidemiology

The prevalence of IgE-mediated FA is highest in infancy and early childhood, driven by a relatively high prevalence of egg and cow's milk allergy that often resolves later in childhood. By contrast, peanut and tree nut allergy, which also typically present in infancy, are less likely to resolve and therefore predominate in later childhood²¹. Marked differences in the prevalence of FA between countries have been noted for multiple foods, although data from some countries remains sparse²²⁻²⁶. More recent studies have shown that large differences in FA prevalence can exist even within individual countries, with some of this difference driven by a lower prevalence in rural areas compared with urban areas^{4,27,28}. Reasons for these differences are largely speculative, with differences in the prevalence of the risk factors described below potentially playing a role.

The strongest known risk factor for FA is probably eczema, particularly eczema which starts early in life and is more severe^{27,28}. This finding has been noted consistently across studies in both population-based studies and in allergy clinics for many years; however, the mechanism driving this association remains unclear. It has been hypothesised that a damaged skin barrier resulting from eczema may allow the absorption of food allergens through the skin leading to food sensitisation and allergy, in the absence of pre-existing oral tolerance to those foods²⁹. Alternative explanations include the existence of shared genetic or environmental risk factors leading to an increased risk of both eczema and FA.

There has been strong interest in identifying factors that can be modified to prevent FA. Both observational studies and randomised controlled trials have investigated the association between FA and factors including vitamin supplements, fish oil, probiotics and timing of introduction of allergenic foods. These are described further below in the FA prevention

section. Other factors that have been associated with risk of FA include factors potentially associated with increased microbial exposure such as pet dogs and older siblings^{30,31}.

Mechanisms and pathophysiology

T cells are central coordinators of the immune response to food allergens, namely the production of antibodies by B cells, and understanding the underlying immune mechanism can help us identify targets for treatment and other interventions to prevent and reduce the impact of FA. Using mass cytometry for immunoprofiling of infants, Neeland et al³² described cellular fingerprints associated with peanut allergy and tolerance amongst IgE sensitised infants. Peanut allergic infants had increased frequency of CD19^{hi}HLA-DR^{hi} activated B cells and of peanut-specific memory CD4⁺ T cells as well as overproduction of TNFalpha whereas peanut sensitised tolerant infants had reduced frequency of CD4⁺ naïve T cells and an increased frequency of plasmacytoid dendritic cells. Following the description of the new subset of Th2 cells typical of highly allergic patients, the TH2A cells, and that decreased following allergen-specific immunotherapy by Wambre et al³³, Chiang et al³⁴ found highly differentiated Th2 cells in the peripheral blood of peanut allergic patients that were resistant to the counter effect induced by regulatory T cells whereas healthy controls did not have detectable T cell responses to peanut. A stability of T regulatory response was reported by Weissler et al³⁵ in both allergic and non-allergic subjects, with a Th2 and Th1-skewed peanut response detected in sensitised and non-sensitised individuals, respectively. However, Pellerin et al found that Tr1 cells were functionally impaired in peanut allergic compared to healthy controls. Ruiter et al³⁶ studied the TCR repertoire of CD154⁺CD4⁺ memory T cells and found strong convergent selection of peanut-specific clones that were more numerous among effector T cells of peanut allergic patients, with an imbalance between effector and regulatory T cells. The more reactive patients had a more diverse and polarised Th2 effector phenotype with the expression of Th2 cytokines correlating with peanut-specific IgE levels. Recently, new studies have shed light on the role of antibodies in allergy and tolerance and on the still puzzling discrepancy between the presence of allergen-specific IgE and clinical reactivity to foods. For instance, a new subset of T follicular helper cell has been identified in the germinal centre and designated Tfh13 cells³⁷. Tfh13 cells are characterised by a distinct transcription factor profile, that includes BCL6 and GATA-3, and by the production of IL-4 and

IL-13. Tfh13 result in high affinity IgE production that is able to induce anaphylaxis to allergens. This high affinity IgE is most likely a result of indirect isotype switching from IgG1+ to IgE+ B cells. Contrary to IgG and IgE that depend on germinal centres and Tfh cells, IgA seems to follow an independent mechanism that requires T cells and CD40-ligand but is independent of germinal centres, Tfh and T follicular regulatory cells³⁸. Interestingly, Hoh et al³⁹ have shown that the class switch recombination from IgG to IgE and the somatic hypermutation that lead to increased affinity for allergens could develop in the gut of peanut allergic individuals, underscoring the importance of gut-associated lymphoid tissue in FA.

Apart from intrinsic characteristics of IgE, like affinity for allergens, post-translational modifications such as glycosylation can have an impact in the ability of IgE to cause effector cell activation and consequently allergic reactions. In a recent study, Shade et al⁴⁰ reported that total IgE from peanut allergic had higher sialic acid content compared to non-atopic subjects and that desialylation of IgE reduced effector cell degranulation and consequent anaphylaxis, raising a new possibility for intervention in treating allergic disease, including FA. These differences in T and B cell responses and antibody profile modulate the effector cell response. Hemmings et al⁴¹ showed that Ara h 2-specific IgE induced greater inhibition of IgE binding and greater mast cell degranulation than Ara h 6, confirming that despite sequence and structural similarities between Ara h 2 and Ara h 6 and the fact that both are major allergens in peanut, Ara h 2 is the dominant allergen. Effector cell response to allergen can support the identification of phenotypes of food allergic patients that may deserve different type of follow up and may have indication for specific treatments, such as allergen-specific immunotherapy or biologics. Patil et al⁴² assessed basophil responses to Ara h 2 in peanut allergic patients at baseline and at different time points during peanut oral immunotherapy (OIT). Basophil sensitivity, defined by the concentration at which basophils reacted, after 3 months of OIT, could distinguish the patients who responded had sustained unresponsiveness at the end of the trial from the patients who had transient desensitisation and whose basophil response to Ara h 2 rebounded after stopping OIT.

To conclude, understanding the immune mechanisms underlying FA and oral tolerance is key to improve diagnostics and the care for patients and their families and identify targets for a definitive treatment of FA. Table 1 summarizes recent new discoveries about immune mechanisms of FA.

Diagnosis

An accurate diagnosis of FA is essential. Correctly identifying FA is crucial for providing education and management strategies to mitigate the risks of a potentially life-threatening allergic reactions. In contrast, correctly identifying food tolerance will promote dietary liberation which is especially important in light of the paradigm shift encouraging early introduction of allergenic foods to prevent FA.⁴³ Double-blind placebo-controlled food challenges remain the gold standard of FA diagnosis. However, due to the inherent risks and intensive resource requirements, their feasibility is limited in some clinical and research settings.

Skin prick tests (SPT) and serum-specific IgE (sIgE) are routinely used in clinical practice and are relatively safe and inexpensive to perform. However, the conventional positive results (SPT \geq 3mm or sIgE \geq 0.35ku/l) have poor specificity to clinical FA, with approximately half of sensitised individuals able to tolerate the food without reaction. As increasing magnitude of these tests correlates to a higher risk of reaction, many studies have defined thresholds for these tests with 95% positive predictive value (PPV) to FA (reviewed in ⁴⁴⁻⁴⁹). Although SPT and sIgE thresholds with 95% PPV to FA are routinely used to minimise the need for diagnostic food challenges, a proportion of children remain in the immunological grey area, that is, they are food sensitised but below the 95% PPV threshold. New approaches that can accurately diagnose FA while reducing the need for food challenges are urgently needed.

Allergen component-resolved diagnostics (CRD) are proposed as a more accurate method of diagnosis, because instead of using crude allergen extracts which consist of both allergenic and non-allergenic components, CRD measures sIgE to individual allergen proteins. A systematic review comparing SPT and sIgE to whole peanut and its components concluded that sIgE to ara h2 had greater diagnostic accuracy compared to the other tests.⁴⁷ Furthermore, a meta-analysis of 19 studies found that while sIgE to Arah 1, 2 and 3 had high specificity to peanut allergy, sensitivity was highest Arah 2. The pooled sensitivity and specificity of Arah2 \geq 0.35kU/L to peanut allergy was 83% (95% CI 76-89%) and 84% (95% CI 77-88%).⁵⁰ Likewise, further studies support that component resolved diagnostics offer greater accuracy compares to sIgE to whole allergens for hazelnut ⁵¹ and it is plausible that this increased accuracy applies to other foods. The major allergen components for most

common food allergens have been isolated and research continues to identify the optimal cut-off points.⁵²

Molecular approaches to the diagnosis of FA also appear to offer greater sensitivity and specificity than traditional tests. The basophil activation test measures the expression of activation markers on the surface of basophils stimulated with food allergens and controls, by flow cytometry.⁵³ In a study of 109 children, BAT demonstrated superior ability to discriminate between peanut allergic and sensitized- tolerant children compared to SPT, sIgE and sIgE to ara h2. The optimal diagnostic parameter and threshold demonstrated an impressive sensitivity and specificity of 98% (95% CI 87-100) and 96% (95% CI 86-100) respectively. BAT performed similarly well when validated in an independent sample (83% sensitivity and 100% specificity).⁵⁴ For other allergens, BAT performed well but not necessarily superior to other measures. In a prospective study of 83 children with suspected tree nut allergy, SPT demonstrated greater sensitivity to BAT, while BAT demonstrated greater specificity compared to SPT; AUC was similar for both measures with the exception of hazelnut where BAT had greater AUC than SPT⁵⁵. While the performance of BAT appears promising, its clinical utility may be limited because it requires live cells and flow cytometry equipment. BAT may therefore be more feasible in settings where it can be used in combination with conventional diagnostic tests. For example, performing peanut BAT as a second step following equivocal SPT or sIgE to Ara h2, reduced the need for OFC by 97% compared to the combination of SPT and sIgE to whole peanut.⁵⁴

Mast cell activation tests offer another promising approach and have the advantage over BAT that they use stored plasma rather than fresh whole blood. In the same sample as described previously for peanut BAT⁵⁴ MAT performed equally well to BAT in terms of specificity, however the sensitivity of MAT was lower than BAT. Importantly, MAT provided definitive results in all cases where basophils were non-responsive.⁵⁶ In a smaller study, MAT performed better than BAT based on AUC for the diagnosis of peanut allergy, however confidence intervals overlapped.⁵⁷ The utility of these test has been assessed for some other common allergens and performs similarly well other further research is needed.⁵⁸ Additionally, these molecular approaches may offer additional clinical utility as the results are correlated to reaction severity^{57,58}, whereas SPT and sIgE are not always predictive of reaction severity^{59,60}. However further work is required to inform standardisation of laboratory procedures, optimal

test parameters and thresholds, and cost-effectiveness in different settings before these novel approaches are ready for routine clinical practice.⁵³

Despite continued advances and development of novel molecular techniques, identifying a definitive diagnostic test to negate the need for oral food challenges remains elusive. The optimal threshold requires a trade-off between false negatives false positives and this varies in the published literature due to heterogeneity in study sample, design, methods, regional characteristics, allergen extracts and laboratory procedures. Figure 1 represents a suggested approach to the sequential use of diagnostic tests. Identification, validation, and cost-effectiveness of the optimal diagnostic approach for FA continues to be an active area of research.

Treatment

Allergen avoidance

In absence of effective treatment, allergen avoidance and providing appropriate emergency medication used to be the only approach to management of food allergy (FA).¹ Avoidance of food allergen is onerous for patients and families and often fails with ten per cent of patients on average experiencing an allergic reaction per year.^{2 3 4} Additionally, allergen avoidance inflicts multiple pressures on allergic individuals and their families, food manufacturers and restaurants as well as public spaces such as schools or aircrafts.^{5 6} Precautionary allergen labelling is in general voluntary and used inconsistently across industry which is misleading for patients and caregivers.²

Providing adrenaline autoinjectors (AAI) to patients at risk of anaphylaxis encounters challenges related to their availability which is mostly limited to high-income countries, varied national regulations in prescribing and high cost.⁷ When prescribed, AAI are only carried at all times by half of the patients⁸ and mistakes in use are frequent among both patients⁹ and medical staff.¹⁰

Meeting the needs of both food allergic children undergoing immunotherapy and those continuing strict avoidance in the same environment, e.g. school or household with two allergic siblings managed differently is an arising challenge.

Food immunotherapy

Just over twenty years since the first RCT showed its high efficacy ¹¹, food immunotherapy (FIT) has become the first established treatment modality for food allergy (FA) which is now recommended by national and international guidelines. ^{12 13 14} High efficacy of oral FIT has been consistently confirmed in RCT in children with milk, egg and peanut allergy ¹⁵ while slightly lower desensitization rates were achieved in wheat allergy. ¹⁶ In the largest oral FIT study so far, the PALISADE Study, which investigated efficacy of 300 mg dose of peanut protein in inducing tolerance to peanut in almost 500 children ≥ 4 years, 67.2% of participants achieved the primary end point of passing 600 mg dose at the exit DBPCFC. ¹⁷ It has also been confirmed recently in a placebo controlled study that peanut oral IT (POIT) significantly reduces the risk of reaction after accidental exposure to peanut (placebo group, 24 reactions in 14 patients; active group, 8 reactions in 5 patients; $p < 0.001$). ¹⁸ Nevertheless, the recent safety metanalysis which looked into 12 POIT studies estimated that the risk of anaphylaxis while on POIT is over three times higher compared to peanut avoidance (RR, 3.12, 95% CI 1.76-5.55) and the risk of adrenaline use is over twice as high (RR, 2.21; 95% CI 1.27-3.83). ¹⁹ Therefore, the current focus of FIT research is orientated towards answering crucial questions about increasing safety of FIT by choosing well-tolerated and effective formulation, route and dose, adding adjuvants at the initial stage of the treatment and identifying patients most likely to benefit from FIT. The other main need is understanding long-term outcomes of the treatment. ^{20 21} Table 2 summarises recent developments in FIT and Figure 2 illustrates phenotypes of food allergy and possible outcomes of FIT.

Despite satisfying efficacy in inducing desensitization to the culprit food, the outcome of FIT differs from natural outgrowing of FA. While the benefits of a margin of protection in case of accidental exposure and introducing certain amount of the food in regular diet are enjoyed during the treatment, the long term effect remains unpredictable with up to 70 per cent successfully desensitised individuals losing tolerance after a short period of avoidance. ³⁶ Why the post-IT tolerance is lost despite apparent similarities with outgrowing in immunological response (decrease in specific IgE concentration and raise in specific IgG4), remains unclear. ³⁷ As SU is not achieved by at least half of the patients, the question remains about the necessary frequency of consumption of the food after completion of FIT. Reassuringly, twice a week consumption of an egg has proven sufficient to sustain tolerance in the Spanish SEICAP Study. ³⁹ In the large long-term follow up Finnish cohort of children who completed milk OIT,

only a quarter of the children returned to milk avoidance diet during the median 6.5 yearlong observation period.⁴⁰ Regarding ongoing peanut consumption, 64% of previous peanut IT participants continued to ingest peanut daily and another 25% less frequently. Unfortunately, allergic reactions including airway involvement were still noted even in this late stage of desensitization.⁴¹ With the first commercial product for peanut OIT approved by FDA in January 2020, FIT is likely to become more available and uniform in the coming years.

Biologicals

In FA, biological treatments have been mostly investigated in the context of facilitating FIT. In addition to the above mentioned FIT/anti-IgE studies which have already been completed, there are ongoing projects looking at use of dupilumab in combination with peanut OIT (Clinicaltrials.gov NCT03793608, Clinicaltrials.gov NCT03682770), combination of dupilumab and omalizumab in multi-food OIT (Clinicaltrials.gov NCT03679676) as well as anti-IL-33 in peanut OIT (Clinicaltrials.gov NCT02920021).⁴²

Due to its pathomechanism, eosinophilic pathway inhibition has been extensively studied in the treatment of EoE.⁴³ The use of anti-IL-5, anti-IL-13 and anti-IL-4 has been associated with significant reduction of histological features of EoE in three RCT.^{44 45} However, there have been no clear clinical improvement noted. Therefore, the treatments are currently not routinely recommended in EoE management.⁴⁶

It has been shown in recent mice study that inhibition of alarmins (IL-25, IL-33 and TSLP) may be effective in preventing FA⁴⁷ which may suggest future promising direction of biological use in FA.

Prevention

Despite significant progress in identifying risk factors for FA, there is still little that can be recommended to prevent FA. Few of the known risk factors described above are easily modifiable. Furthermore, of the potentially modifiable factors tested in clinical trials to date, most have not been effective in preventing FA. A recent systematic review by the European Academy of Allergy, Clinical Immunology FA, Anaphylaxis Guidelines Group¹⁰⁸ identified 41 randomised controlled trials of potential FA prevention strategies in infancy and childhood. The vast majority of these trials showed little to no effect on preventing FA, including trials of

dietary avoidance of food allergens, vitamin supplements (maternal and infant), fish oil, probiotics, prebiotics, symbiotics, and hydrolysed formulas. However, the authors also concluded that the evidence around most of these interventions remains very uncertain. Many of the trials were at risk of bias due to lack of robust diagnostic criteria, high loss to follow-up, potential confounding, and lack of blinding and were underpowered for the outcome of interest.

Although some of the risk of FA is likely to be already established at birth, to date there are no known effective preventative strategies that can be applied during pregnancy. The only intervention that is currently widely recommended to reduce the risk of FA is timely introduction of peanut into the infant diet. This recommendation is primarily based on the results of a large, high quality randomised controlled trial in high risk infants conducted in the United Kingdom⁹ - a country with a relatively high prevalence of FA. The relevance of these findings to countries with a low peanut allergy prevalence is less clear¹⁰⁹. There is also evidence from meta-analyses of multiple trials that early introduction of egg into the infant diet reduces the risk of egg allergy, although the extent of the reduction in risk appears lower than for peanut⁴³.

Conclusion

FA is a major public health issue with growing prevalence in the urbanized world and significant impact on the lives of allergic patients and their families. Research into the risk factors that have contributed to this increase and their underlying mechanisms could pave the way to definitive ways for treatment and prevention of FA. For the time being, introduction of peanut and other allergenic foods in the diet at the time of weaning seems to be an effective way to prevent the development of FA. Improved diagnosis and appropriate management and support of food allergic patients is central to patient care with food immunotherapy and biologicals making the transition to clinical practice. With the new available treatments it is becoming increasingly important to include patient's and family preferences to provide a management plan tailored to their needs.

Tables

Table 1. Highlights of new discoveries about immune mechanisms of food allergy

T cells and T follicular helper cells	<ul style="list-style-type: none"> • Food allergy involves Th2-skewed response more than a dysregulated regulatory T cell population^{34,35}. • The new subset of Tfh cells Tfh13 induces the sequential class switching from IgG1 to IgE leading to the production of high affinity IgE that can cause anaphylaxis³⁷.
B cells and antibodies	<ul style="list-style-type: none"> • IgE class switching can happen in the gut-associated lymphoid tissue³⁹. • IgA induces tolerance through immune exclusion rather than active suppression and is generated via a separate mechanism that is independent of Tfh and germinal centres³⁸.
Basophils and mast cells	<ul style="list-style-type: none"> • IgE glycosylation enhances effector cell degranulation⁴⁰. • Basophil response to allergen can distinguish responders from non-responders as early as 3 months into oral immunotherapy⁴².

Table 2. Recent developments in food immunotherapy.

Route	<ul style="list-style-type: none"> • Safety profile of sublingual IT (SLIT) and epicutaneous IT (EPIT) is favourable with hardly any systemic allergic reactions reported; it comes however at the cost of lower efficacy. ^{26,27} • In the large phase 3 study on EPIT to peanut, 35.3% of participants achieved predefined response rate compared to 13.6% of children in placebo group; despite the difference being statistically significant, the 95% CI exceeded prespecified lower cut-off which means the study did not meet its primary end point. ²⁸ • The modest level of desensitization predisposes SLIT and EPIT for use in individuals not tolerating OIT. ²⁷ • Longer treatment duration may be necessary to achieve results comparable with OIT. ²⁹
Dose	<ul style="list-style-type: none"> • Daily dose equivalent of one peanut and ten peanuts exert similar clinical and immunological effects in peanut IT in young children. ²⁴ • Using lower dose of the food seems to have a favourable effect on safety. No use of adrenaline related to treatment was reported in the recent peanut OIT study in which maintenance peanut protein dose was established between 125 mg and 250 mg. ¹⁸ • However, in the group of Japanese children with history of anaphylaxis to wheat, 31% of subjects developed mild anaphylaxis despite low-dose protocol (53 mg of wheat protein). ²⁵
Age	<ul style="list-style-type: none"> • FIT tends to be associated with reassuring safety profile and higher rates of sustained unresponsiveness if started early. ²⁴ • In the Italian cohort of 73 infants with IgE-mediated milk allergy who underwent milk OIT, 97% reached the target 150 mL dose of milk. No patient required use of AAI at home. ³⁰
Formulation	<ul style="list-style-type: none"> • Well-known phenomenon of decreased allergenicity of thermally processed food ²² has been used in proof of concept FT studies. • The BOPI Study looked into effectiveness and safety of boiled peanut IT. 28% of participants presented with 1.9 episodes of anaphylaxis during treatment which is comparable to average rate of severe adverse events reported in other studies. • Bird <i>et al</i>/ confirmed in a small proof of concept study that baked egg IT led to desensitization to lightly cooked egg with no moderate or severe adverse events noted. ²³

	<ul style="list-style-type: none"> • The publication of CoFAR7 project comparing baked and fresh egg IT is awaited [ClinicalTrials.gov Identifier: NCT01846208].
Adjuvants	<ul style="list-style-type: none"> • Multiple adjuvant agents have been tested in the context of improving benefit-risk ratio in FIT, from probiotics and Chinese herb medicine through montelukast and antihistamines to biological treatments.³¹ • Anti-IgE has been the most extensively studied including RCTs.³² • Omalizumab allows quicker up-dosing with fewer adverse events without affecting immunological desensitization processes.³¹ • However, omalizumab may potentially mask early symptoms of gastrointestinal disease related to FIT.³³ • Additionally, adverse events may start occurring after discontinuation of anti-IgE in maintenance phase.^{34,35}
Sustained unresponsiveness	<ul style="list-style-type: none"> • The baseline epitope-specific antibody binding models can achieve even 87% accuracy in predicting SU in milk OIT.³⁸ • In peanut OIT, early decrease in basophil sensitivity to Ara h 2 correlates with SU.³⁶ • Higher baseline peanut-specific IgG4 to IgE ratio and lower Ara h 2 IgE and basophil activation responses were associated with sustained unresponsiveness in the POISED Study.

Figures and figure legends

Figure 1. Proposed use of components-specific IgE, basophil and mast cell activation tests in combination with conventional tests (skin prick test and specific IgE) to reduce the need for oral food challenges (OFC).





Figure 2. Clinical phenotypes of food sensitized and food allergic children and possible outcomes of food immunotherapy.



References

1. Gupta RS, Warren CM, Smith BM, et al. The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States. *Pediatrics*. 2018;142(6).
2. Le TTK, Nguyen DH, Vu ATL, Ruethers T, Taki AC, Lopata AL. A cross-sectional, population-based study on the prevalence of food allergies among children in two different socio-economic regions of Vietnam. *Pediatr Allergy Immunol*. 2019;30(3):348-355.
3. Tham EH, Leung ASY, Pacharn P, et al. Anaphylaxis - Lessons learnt when East meets West. *Pediatr Allergy Immunol*. 2019;30(7):681-688.
4. Botha M, Basera W, Facey-Thomas HE, et al. Rural and urban food allergy prevalence from the South African Food Allergy (SAFFA) study. *J Allergy Clin Immunol*. 2019;143(2):662-668 e662.
5. Prescott S, Allen KJ. Food allergy: riding the second wave of the allergy epidemic. *Pediatr Allergy Immunol*. 2011;22(2):155-160.
6. Turner PJ, Gowland MH, Sharma V, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: An analysis of United Kingdom national anaphylaxis data, 1992-2012. *J Allergy Clin Immunol*. 2014.
7. Mullins RJ, Wainstein BK, Barnes EH, Liew WK, Campbell DE. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. *Clin Exp Allergy*. 2016;46(8):1099-1110.
8. Pouessel G, Beaudouin E, Tanno LK, et al. Food-related anaphylaxis fatalities: Analysis of the Allergy Vigilance Network((R)) database. *Allergy*. 2019;74(6):1193-1196.
9. Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. *N Engl J Med*. 2015;372(9):803-813.
10. Perkin MR, Logan K, Tseng A, et al. Randomized Trial of Introduction of Allergenic Foods in Breast-Fed Infants. *N Engl J Med*. 2016;374(18):1733-1743.
11. Branum AM, Lukacs SL. Food allergy among children in the United States. *Pediatrics*. 2009;124(6):1549-1555.
12. Koplin JJ, Peters RL, Ponsonby AL, et al. Increased risk of peanut allergy in infants of Asian-born parents compared to those of Australian-born parents. *Allergy*. 2014;69(12):1639-1647.
13. Yanagida N, Ebisawa M, Katsunuma T, Yoshizawa J. Accidental ingestion of food allergens: A nationwide survey of Japanese nursery schools. *Pediatr Allergy Immunol*. 2019;30(7):773-776.
14. Meyer R. Nutritional disorders resulting from food allergy in children. *Pediatr Allergy Immunol*. 2018;29(7):689-704.
15. Dilley MA, Rettiganti M, Christie L, et al. Impact of food allergy on food insecurity and health literacy in a tertiary care pediatric allergy population. *Pediatr Allergy Immunol*. 2019;30(3):363-369.
16. Goldberg MR, Nachshon L, Sinai T, et al. Risk factors for reduced bone mineral density measurements in milk-allergic patients. *Pediatr Allergy Immunol*. 2018;29(8):850-856.
17. Beken B, Celik V, Gokmirza Ozdemir P, Sut N, Gorker I, Yazicioglu M. Maternal anxiety and internet-based food elimination in suspected food allergy. *Pediatr Allergy Immunol*. 2019;30(7):752-759.
18. Fong AT, Katelaris CH, Wainstein BK. Bullying in Australian children and adolescents with food allergies. *Pediatr Allergy Immunol*. 2018;29(7):740-746.
19. Avery NJ, King RM, Knight S, Hourihane JO. Assessment of quality of life in children with peanut allergy. *Pediatr Allergy Immunol*. 2003;14(5):378-382.
20. King RM, Knibb RC, Hourihane JO. Impact of peanut allergy on quality of life, stress and anxiety in the family. *Allergy*. 2009;64(3):461-468.
21. Peters RL, Koplin JJ, Gurrin LC, et al. The prevalence of food allergy and other allergic diseases in early childhood in a population-based study: HealthNuts age 4-year follow-up. *J Allergy Clin Immunol*. 2017;140(1):145-153 e148.

22. Venter C, Maslin K, Patil V, et al. The prevalence, natural history and time trends of peanut allergy over the first 10 years of life in two cohorts born in the same geographical location 12 years apart. *Pediatr Allergy Immunol.* 2016;27(8):804-811.
23. Venter C, Patil V, Grundy J, et al. Prevalence and cumulative incidence of food hypersensitivity in the first 10 years of life. *Pediatr Allergy Immunol.* 2016;27(5):452-458.
24. Schoemaker AA, Sprickelman AB, Grimshaw KE, et al. Incidence and natural history of challenge-proven cow's milk allergy in European children--EuroPrevall birth cohort. *Allergy.* 2015;70(8):963-972.
25. Xepapadaki P, Fiocchi A, Grabenhenrich L, et al. Incidence and natural history of hen's egg allergy in the first 2 years of life-the EuroPrevall birth cohort study. *Allergy.* 2016;71(3):350-357.
26. Osborne NJ, Koplin JJ, Martin PE, et al. Prevalence of challenge-proven IgE-mediated food allergy using population-based sampling and predetermined challenge criteria in infants. *J Allergy Clin Immunol.* 2011;127(3):668-676 e661-662.
27. Martin PE, Eckert JK, Koplin JJ, et al. Which infants with eczema are at risk of food allergy? Results from a population-based cohort. *Clin Exp Allergy.* 2015;45(1):255-264.
28. Grimshaw KEC, Roberts G, Selby A, et al. Risk Factors for Hen's Egg Allergy in Europe: EuroPrevall Birth Cohort. *J Allergy Clin Immunol Pract.* 2020;8(4):1341-1348 e1345.
29. Lack G. Epidemiologic risks for food allergy. *J Allergy Clin Immunol.* 2008;121(6):1331-1336.
30. Marrs T, Bruce KD, Logan K, et al. Is there an association between microbial exposure and food allergy? A systematic review. *Pediatr Allergy Immunol.* 2013;24(4):311-320 e318.
31. Koplin JJ, Dharmage SC, Ponsonby AL, et al. Environmental and demographic risk factors for egg allergy in a population-based study of infants. *Allergy.* 2012;67(11):1415-1422.
32. Neeland MR, Andorf S, Manohar M, et al. Mass cytometry reveals cellular fingerprint associated with IgE+ peanut tolerance and allergy in early life. *Nat Commun.* 2020;11(1):1091.
33. Wambre E, Bajzik V, DeLong JH, et al. A phenotypically and functionally distinct human TH2 cell subpopulation is associated with allergic disorders. *Sci Transl Med.* 2017;9(401).
34. Chiang D, Chen X, Jones SM, et al. Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector TH2 subsets. *J Allergy Clin Immunol.* 2018;141(6):2107-2120.
35. Weissler KA, Rasooly M, DiMaggio T, et al. Identification and analysis of peanut-specific effector T and regulatory T cells in children allergic and tolerant to peanut. *J Allergy Clin Immunol.* 2018;141(5):1699-1710 e1697.
36. Ruiter B, Smith NP, Monian B, et al. Expansion of the CD4(+) effector T-cell repertoire characterizes peanut-allergic patients with heightened clinical sensitivity. *J Allergy Clin Immunol.* 2020;145(1):270-282.
37. Gowthaman U, Chen JS, Zhang B, et al. Identification of a T follicular helper cell subset that drives anaphylactic IgE. *Science.* 2019;365(6456).
38. Zhang B, Liu E, Gertie JA, et al. Divergent T follicular helper cell requirement for IgA and IgE production to peanut during allergic sensitization. *Sci Immunol.* 2020;5(47).
39. Hoh RA, Joshi SA, Lee JY, et al. Origins and clonal convergence of gastrointestinal IgE(+) B cells in human peanut allergy. *Sci Immunol.* 2020;5(45).
40. Shade KC, Conroy ME, Washburn N, et al. Sialylation of immunoglobulin E is a determinant of allergic pathogenicity. *Nature.* 2020;582(7811):265-270.
41. Hemmings O, Du Toit G, Radulovic S, Lack G, Santos AF. Ara h 2 is the dominant peanut allergen despite similarities with Ara h 6. *J Allergy Clin Immunol.* 2020.
42. Patil SU, Steinbrecher J, Calatroni A, et al. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy. *J Allergy Clin Immunol.* 2019;144(5):1310-1319 e1314.

43. Ierodiakonou D, Garcia-Larsen V, Logan A, et al. Timing of Allergenic Food Introduction to the Infant Diet and Risk of Allergic or Autoimmune Disease: A Systematic Review and Meta-analysis. *JAMA*. 2016;316(11):1181-1192.
44. Peters RL, Gurrin LC, Allen KJ. The predictive value of skin prick testing for challenge-proven food allergy: a systematic review. *Pediatr Allergy Immunol*. 2012;23(4):347-352.
45. Peters RL, Gurrin LC, Dharmage SC, Koplin JJ, Allen KJ. The natural history of IgE-mediated food allergy: can skin prick tests and serum-specific IgE predict the resolution of food allergy? *Int J Environ Res Public Health*. 2013;10(10):5039-5061.
46. Cuomo B, Indirli GC, Bianchi A, et al. Specific IgE and skin prick tests to diagnose allergy to fresh and baked cow's milk according to age: a systematic review. *Ital J Pediatr*. 2017;43(1):93.
47. Klemans RJ, van Os-Medendorp H, Blankestijn M, Bruijnzeel-Koomen CA, Knol EF, Knulst AC. Diagnostic accuracy of specific IgE to components in diagnosing peanut allergy: a systematic review. *Clin Exp Allergy*. 2015;45(4):720-730.
48. Soares-Weiser K, Takwoingi Y, Panesar SS, et al. The diagnosis of food allergy: a systematic review and meta-analysis. *Allergy*. 2014;69(1):76-86.
49. Calvani M, Arasi S, Bianchi A, et al. Is it possible to make a diagnosis of raw, heated, and baked egg allergy in children using cutoffs? A systematic review. *Pediatr Allergy Immunol*. 2015;26(6):509-521.
50. Nilsson C, Berthold M, Mascialino B, Orme ME, Sjolander S, Hamilton RG. Accuracy of component-resolved diagnostics in peanut allergy: Systematic literature review and meta-analysis. *Pediatr Allergy Immunol*. 2019.
51. Nilsson C, Berthold M, Mascialino B, Orme M, Sjolander S, Hamilton R. Allergen components in diagnosing childhood hazelnut allergy: Systematic literature review and meta-analysis. *Pediatr Allergy Immunol*. 2020;31(2):186-196.
52. Flores Kim J, McCleary N, Nwaru BI, Stoddart A, Sheikh A. Diagnostic accuracy, risk assessment, and cost-effectiveness of component-resolved diagnostics for food allergy: A systematic review. *Allergy*. 2018;73(8):1609-1621.
53. Santos AF, Shreffler WG. Road map for the clinical application of the basophil activation test in food allergy. *Clin Exp Allergy*. 2017;47(9):1115-1124.
54. Santos AF, Douiri A, Becares N, et al. Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children. *J Allergy Clin Immunol*. 2014;134(3):645-652.
55. Elizur A, Appel MY, Nachshon L, et al. NUT Co Reactivity - ACquiring Knowledge for Elimination Recommendations (NUT CRACKER) study. *Allergy*. 2018;73(3):593-601.
56. Santos AF, Couto-Francisco N, Becares N, Kwok M, Bahnson HT, Lack G. A novel human mast cell activation test for peanut allergy. *J Allergy Clin Immunol*. 2018;142(2):689-691 e689.
57. Bahri R, Custovic A, Korosec P, et al. Mast cell activation test in the diagnosis of allergic disease and anaphylaxis. *The Journal of allergy and clinical immunology*. 2018;142(2):485-496 e416.
58. Song Y, Wang J, Leung N, et al. Correlations between basophil activation, allergen-specific IgE with outcome and severity of oral food challenges. *Ann Allergy Asthma Immunol*. 2015;114(4):319-326.
59. van Erp FC, Knulst AC, Kentie PA, Pasmans SG, van der Ent CK, Meijer Y. Can we predict severe reactions during peanut challenges in children? *Pediatr Allergy Immunol*. 2013;24(6):596-602.
60. Santos AF, Du Toit G, O'Rourke C, et al. Biomarkers of severity and threshold of allergic reactions during oral peanut challenges. *J Allergy Clin Immunol*. 2020.
61. Muraro A, Werfel T, Hoffmann-Sommergruber K, et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. *Allergy*. 2014;69(8):1008-1025.
62. Graham F, Caubet JC, Eigenmann PA. Can my child with IgE-mediated peanut allergy introduce foods labeled with "may contain traces"? *Pediatr Allergy Immunol*. 2020.

63. Shaker M, Greenhawt M. Providing cost-effective care for food allergy. *Ann Allergy Asthma Immunol*. 2019;123(3):240-248.e241.
64. Capucilli P, Wang KY, Spergel JM. Food reactions during avoidance: Focus on peanut. *Ann Allergy Asthma Immunol*. 2020;124(5):459-465.
65. Abrams EM, Greenhawt M. The role of peanut-free school policies in the protection of children with peanut allergy. *J Public Health Policy*. 2020.
66. Shaker M, Greenhawt M. Cost-Effectiveness of Stock Epinephrine Autoinjectors on Commercial Aircraft. *J Allergy Clin Immunol Pract*. 2019;7(7):2270-2276.
67. Tanno LK, Demoly P, Academies JA. Action Plan to Ensure Global Availability of Adrenaline Autoinjectors. *J Investig Allergol Clin Immunol*. 2020;30(2):77-85.
68. Portnoy J, Wade RL, Kessler C. Patient Carrying Time, Confidence, and Training with Epinephrine Autoinjectors: The RACE Survey. *J Allergy Clin Immunol Pract*. 2019;7(7):2252-2261.
69. Sasaki K, Nakagawa T, Sugiura S, Ebisawa M, Ito K. Identifying the factors and root causes associated with the unintentional usage of an adrenaline auto-injector in Japanese children and their caregivers. *Allergol Int*. 2018;67(4):475-480.
70. Maa T, Scherzer DJ, Harwayne-Gidansky I, et al. Prevalence of Errors in Anaphylaxis in Kids (PEAK): A Multicenter Simulation-Based Study. *J Allergy Clin Immunol Pract*. 2020;8(4):1239-1246.e1233.
71. Patriarca G, Schiavino D, Nucera E, Schinco G, Milani A, Gasbarrini GB. Food allergy in children: results of a standardized protocol for oral desensitization. *Hepatogastroenterology*. 1998;45(19):52-58.
72. Martorell A, Alonso E, Echeverría L, et al. Oral immunotherapy for food allergy: A Spanish guideline. Egg and milk immunotherapy Spanish guide (ITEMS GUIDE). Part 2: Maintenance phase of cow milk (CM) and egg oral immunotherapy (OIT), special treatment dosing schedules. Models of dosing schedules of OIT with CM and EGG. *Allergol Immunopathol (Madr)*. 2017;45(5):508-518.
73. Bégin P, Chan ES, Kim H, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. *Allergy Asthma Clin Immunol*. 2020;16:20.
74. Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. *Allergy*. 2018;73(4):799-815.
75. Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. *Allergy*. 2017;72(8):1133-1147.
76. Nowak-Węgrzyn A, Wood RA, Nadeau KC, et al. Multicenter, randomized, double-blind, placebo-controlled clinical trial of vital wheat gluten oral immunotherapy. *J Allergy Clin Immunol*. 2019;143(2):651-661.e659.
77. Vickery BP, Vereda A, Casale TB, et al. AR101 Oral Immunotherapy for Peanut Allergy. *N Engl J Med*. 2018;379(21):1991-2001.
78. Blumchen K, Trendelenburg V, Ahrens F, et al. Efficacy, Safety, and Quality of Life in a Multicenter, Randomized, Placebo-Controlled Trial of Low-Dose Peanut Oral Immunotherapy in Children with Peanut Allergy. *J Allergy Clin Immunol Pract*. 2019;7(2):479-491.e410.
79. Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. *Lancet*. 2019;393(10187):2222-2232.
80. Vázquez-Cortés S, Jaqueti P, Arasi S, Machinena A, Alvaro-Lozano M, Fernández-Rivas M. Safety of Food Oral Immunotherapy: What We Know, and What We Need to Learn. *Immunol Allergy Clin North Am*. 2020;40(1):111-133.
81. Calvani M, Bianchi A, Imondi C, Romeo E. Oral desensitization in IgE-mediated food allergy: Effectiveness and safety. *Pediatr Allergy Immunol*. 2020;31 Suppl 24:49-50.

82. Bloom KA, Huang FR, Bencharitiwong R, et al. Effect of heat treatment on milk and egg proteins allergenicity. *Pediatr Allergy Immunol*. 2014;25(8):740-746.
83. Bird JA, Clark A, Dougherty I, et al. Baked egg oral immunotherapy desensitizes baked egg allergic children to lightly cooked egg. *J Allergy Clin Immunol Pract*. 2019;7(2):667-669.e664.
84. Vickery BP, Berglund JP, Burk CM, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. *J Allergy Clin Immunol*. 2017;139(1):173-181.e178.
85. Nagakura KI, Yanagida N, Sato S, et al. Low-dose-oral immunotherapy for children with wheat-induced anaphylaxis. *Pediatr Allergy Immunol*. 2020;31(4):371-379.
86. Kim EH, Burks AW. Food allergy immunotherapy: OIT and EPIT. *Allergy*. 2020.
87. Waldron J, Kim EH. Sublingual and Patch Immunotherapy for Food Allergy. *Immunol Allergy Clin North Am*. 2020;40(1):135-148.
88. Fleischer DM, Greenhawt M, Sussman G, et al. Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion Among Children With Peanut Allergy: The PEPITES Randomized Clinical Trial. *JAMA*. 2019;321(10):946-955.
89. Kim EH, Yang L, Ye P, et al. Long-term sublingual immunotherapy for peanut allergy in children: Clinical and immunologic evidence of desensitization. *J Allergy Clin Immunol*. 2019;144(5):1320-1326.e1321.
90. Berti I, Badina L, Cozzi G, et al. Early oral immunotherapy in infants with cow's milk protein allergy. *Pediatr Allergy Immunol*. 2019;30(5):572-574.
91. Virkud YV, Wang J, Shreffler WG. Enhancing the Safety and Efficacy of Food Allergy Immunotherapy: a Review of Adjunctive Therapies. *Clin Rev Allergy Immunol*. 2018;55(2):172-189.
92. Lin C, Lee IT, Sampath V, et al. Combining anti-IgE with oral immunotherapy. *Pediatr Allergy Immunol*. 2017;28(7):619-627.
93. Burk CM, Dellon ES, Steele PH, et al. Eosinophilic esophagitis during peanut oral immunotherapy with omalizumab. *J Allergy Clin Immunol Pract*. 2017;5(2):498-501.
94. Martorell-Calatayud C, Michavila-Gómez A, Martorell-Aragonés A, et al. Anti-IgE-assisted desensitization to egg and cow's milk in patients refractory to conventional oral immunotherapy. *Pediatr Allergy Immunol*. 2016;27(5):544-546.
95. Brandstrom J, Vetander M, Sundqvist AC, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. *Clin Exp Allergy*. 2019;49(10):1328-1341.
96. Patil SU, Steinbrecher J, Calatroni A, et al. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy. *J Allergy Clin Immunol*. 2019;144(5):1310-1319.e1314.
97. Soyer OU, Akdis M, Ring J, et al. Mechanisms of peripheral tolerance to allergens. *Allergy*. 2013;68(2):161-170.
98. Suárez-Fariñas M, Suprun M, Chang HL, et al. Predicting development of sustained unresponsiveness to milk oral immunotherapy using epitope-specific antibody binding profiles. *J Allergy Clin Immunol*. 2019;143(3):1038-1046.
99. Martín-Muñoz MF, Alonso Lebrero E, Zapatero L, et al. Egg OIT in clinical practice (SEICAP II): Maintenance patterns and desensitization state after normalizing the diet. *Pediatr Allergy Immunol*. 2019;30(2):214-224.
100. Kaupila TK, Paassilta M, Kukkonen AK, Kuitunen M, Pelkonen AS, Makela MJ. Outcome of oral immunotherapy for persistent cow's milk allergy from 11 years of experience in Finland. *Pediatr Allergy Immunol*. 2019;30(3):356-362.
101. Cook Q, Yang L, Hamad A, et al. Dosing, safety, and quality of life after peanut immunotherapy trials - a long-term follow up study. *J Allergy Clin Immunol Pract*. 2020.
102. Long A, Borro M, Sampath V, Chinthrajah RS. New Developments in Non-allergen-specific Therapy for the Treatment of Food Allergy. *Curr Allergy Asthma Rep*. 2020;20(1):3.

103. Hirano I, Furuta GT. Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis. *Gastroenterology*. 2020;158(4):840-851.
104. Hirano I, Collins MH, Assouline-Dayana Y, et al. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. *Gastroenterology*. 2019;156(3):592-603.e510.
105. Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. *Gastroenterology*. 2020;158(1):111-122.e110.
106. Hirano I, Chan ES, Rank MA, et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. *Gastroenterology*. 2020;158(6):1776-1786.
107. Khodoun MV, Tomar S, Tocker JE, Wang YH, Finkelman FD. Prevention of food allergy development and suppression of established food allergy by neutralization of thymic stromal lymphopoietin, IL-25, and IL-33. *J Allergy Clin Immunol*. 2018;141(1):171-179.e171.
108. de Silva D, Halken S, Singh C, et al. Preventing food allergy in infancy and childhood: systematic review of randomised controlled trials. *Pediatr Allergy Immunol*. 2020.
109. Tham EH, Shek LP, Van Bever HP, et al. Early introduction of allergenic foods for the prevention of food allergy from an Asian perspective-An Asia Pacific Association of Pediatric Allergy, Respiratory & Immunology (APAPARI) consensus statement. *Pediatr Allergy Immunol*. 2018;29(1):18-27.